Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Y-mAbs Therapeutics (NASDAQ:YMAB) has been analyzed by 5 analysts in the last three months, revealing a range of perspectives from bullish to bearish. Analysts have set a 12-month price target average of $20.4, with a high of $25.00 and a low of $11.00. Recent actions include rating adjustments and price target changes by analysts from firms like Morgan Stanley, HC Wainwright & Co., BMO Capital, Jones Trading, and Truist Securities. The company faces challenges with a -1.58% revenue decline over the past three months but shows strong financial metrics like net margin, ROE, and ROA.
August 13, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Y-mAbs Therapeutics has received mixed analyst ratings with a 12-month price target average of $20.4. Recent actions include rating adjustments and price target changes by analysts from Morgan Stanley, HC Wainwright & Co., BMO Capital, Jones Trading, and Truist Securities. The company faces a -1.58% revenue decline over the past three months but shows strong financial metrics like net margin, ROE, and ROA.
The mixed analyst ratings and recent price target adjustments indicate a neutral short-term impact on YMAB's stock price. While the company faces revenue challenges, its strong financial metrics provide a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100